Business
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central ne
About this update from Plus Therapeutics, Inc.
[{"type":"image","alt":"Plus Therapeutics Inc.","displaySize":"","headline":null,"caption":"Plus Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":172,"url":"https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PAd6youIFzv4mViQD8View--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MQ--/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PAd6youIFzv4mViQD8View--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MQ--/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172}},"lazy":false},{"type":"text","content":"Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%","length":137,"tagName":"p"},{"type":"text","content":"Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research","length":146,"tagName":"p"},{"type":"text","content":"HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The Company believes that this cost-of-care analysis underscores that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 33-47%. These savings are driven by earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations. Further, the recently announced payer agreements validate the findings as Plus continues commercialization of the assay in the United States.","length":920,"tagName":"p"},{"type":"text","content":"The data was presented at the ISPOR 2026 Annual Meeting, the leading global scientific conference focused on health economics and outcomes research (HEOR), bringing together researchers, healthcare decision-makers, and payer stakeholders. The meet...